Predict, prioritise & evaluate environmental risk from patient use of legacy & new medicines in the environment

We are part of a multi-disciplinary team delivering a new IMI2-funded platform for the prioritization and risk evaluation of Active Pharmaceutical Ingredients in the environment. We are developing the digital assessment system at the heart of the project, working in partnership with AstraZeneca, GlaxoSmithKline, Bayer, Bristol-Myers Squibb, Novartis, Sanofi, Eli Lilly, Merck and many others.

Learn more about PREMIER

Scroll to Top